Spinal fusion surgery can fail if the bone around the screws is too weak. A new study suggests a drug called romosozumab may make that bone much stronger, which could help the surgery last longer.
This matters because spinal fusion is common in older adults, especially women after menopause. Osteoporosis, a condition that makes bones brittle, raises the risk of complications. When the bone is weak, the screws can loosen or pull out, leading to pain and more surgery.
For years, doctors have used drugs like alendronate or teriparatide to protect bone. But these treatments can take time to work, and they do not always help enough in high risk cases. Patients often worry about whether the surgery will hold.
But here is the twist. Researchers used a clever computer method to test how romosozumab might affect bone around a spinal screw before any real surgery happened. This approach lets them look inside the bone and simulate stress without putting patients at risk.
Think of the bone around a screw like the soil around a fence post. If the soil is loose, the post wobbles and falls. If the soil is packed tight and strong, the post stays put. Romosozumab works like a switch that tells the body to build more dense soil, or bone, around that post.
The drug blocks a protein called sclerostin, which normally slows bone growth. By blocking sclerostin, romosozumab turns on the body’s bone building cells. This can make the bone denser and more resistant to stress, which is exactly what you want around a spinal screw.
The study used CT scans from two large trials in postmenopausal women. One trial compared romosozumab to a placebo and to teriparatide over 12 months. The other trial compared romosozumab followed by alendronate to alendronate alone over 24 months. The researchers created computer models of the lower spine and virtually implanted pedicle screws, then tested how much force the bone could take before failing.
In the first trial, shear bone strength around the screw increased by about 25 percent with romosozumab after 12 months. In contrast, strength dropped slightly with placebo and rose only about 15 percent with teriparatide. The difference was clear and statistically significant.
In the second trial, romosozumab led to a 22 percent increase in strength at six months and a 26 percent increase at 12 months. After switching to alendronate at 12 months, strength stayed high at 25 percent at 24 months. Alendronate alone showed smaller gains, around 6 to 7 percent over the same periods. The amount of bone that would fail under stress also dropped more with romosozumab, and the density around the screw improved.
This does not mean romosozumab is ready for all spinal fusion patients.
The findings come from virtual stress tests, not real surgeries. The women in these imaging substudies were not actually scheduled for spinal fusion. The results suggest potential, but they do not prove clinical benefit yet.
Experts in spine surgery and bone health see promise here. If romosozumab can rapidly strengthen bone around implants, it might help patients heal better after fusion. But doctors will need more data on safety, timing, and how this translates to real world outcomes.
For now, romosozumab is approved for postmenopausal women with osteoporosis at high fracture risk. If you are considering spinal fusion and have weak bones, talk with your doctor about whether this drug could be part of your plan. It is not a quick fix, and it is not a substitute for good surgical technique.
The study has limits. It used computer models, not living patients. The sample sizes were modest, and the follow up periods were relatively short. The results may not apply to men, younger patients, or those with different bone conditions.
Next steps include larger trials that test romosozumab in patients who are actually undergoing spinal fusion. Researchers will look at real world outcomes like screw loosening, pain, and the need for repeat surgery. If those studies confirm the virtual findings, romosozumab could become a useful tool to improve fusion success in women with osteoporosis.
